(Q38119865)

29 August 2017

title

Potential mechanisms of atypical antipsychotic-induced hypertriglyceridemia (English)

1 reference

29 August 2017

Hu Yan

1

1 reference

29 August 2017

Jin-Dong Chen

series ordinal

2

1 reference

29 August 2017

Xiao-Yan Zheng

series ordinal

3

1 reference

29 August 2017

publication date

6 July 2013

1 reference

29 August 2017

1 reference

29 August 2017

volume

229

1 reference

29 August 2017

issue

1

1 reference

29 August 2017

page(s)

1-7

1 reference

Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3193-7

Antipsychotic induced metabolic abnormalities: an interaction study with various PPAR modulators in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3193-7

Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3193-7

Predictors of Weight Loss in Adults with Topiramate‐Treated Epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3193-7

Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3193-7

Heparan sulfate proteoglycans and triglyceride-rich lipoprotein metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3193-7

Preclinical models of antipsychotic drug-induced metabolic side effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3193-7

Selective versus total insulin resistance: a pathogenic paradox

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3193-7

Broad therapeutic uses of atypical antipsychotic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3193-7

The metabolic benefits of Polygonum hypoleucum Ohwi in HepG2 cells and Wistar rats under lipogenic stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3193-7

Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3193-7

Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3193-7

Exploring genetic variations that may be associated with the direct effects of some antipsychotics on lipid levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3193-7

Acetyl-coenzyme A carboxylase alpha gene variations may be associated with the direct effects of some antipsychotics on triglyceride levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3193-7

Lipoprotein lipase. A multifunctional enzyme relevant to common metabolic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3193-7

Association of olanzapine-induced weight gain with an increase in body fat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3193-7

Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3193-7

Sulfonylurea agents exhibit peroxisome proliferator-activated receptor gamma agonistic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3193-7

Treating the metabolic syndrome: acetyl-CoA carboxylase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3193-7

Impact of apolipoprotein A5 (APOA5) polymorphisms on serum triglyceride levels in schizophrenic patients under long-term atypical antipsychotic treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3193-7

SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3193-7

An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3193-7

Efficacy of lipid-lowering medications in patients treated with clozapine: a naturalistic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3193-7

Antipsychotic drug action on SREBPs-related lipogenesis and cholesterogenesis in primary rat hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3193-7

Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3193-7

Novel antipsychotics and severe hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3193-7

The effects of antipsychotic therapy on serum lipids: a comprehensive review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3193-7

Rates of lipid fluxes in adipose tissue in vivo after a mixed meal in morbid obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3193-7

The Scap/SREBP pathway is essential for developing diabetic fatty liver and carbohydrate-induced hypertriglyceridemia in animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3193-7

Olanzapine-induced elevation of serum triglyceride levels in a normal weight patient with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3193-7

Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3193-7

Efficacy of metformin for prevention of weight gain in psychiatric populations: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3193-7

Atypical antipsychotic drugs perturb AMPK-dependent regulation of hepatic lipid metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3193-7

Statins are effective in treating dyslipidemia among psychiatric patients using second-generation antipsychotic agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3193-7

Insulin resistance affects the regulation of lipoprotein lipase in the postprandial period and in an adipose tissue-specific manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3193-7

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3193-7

A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3193-7

Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3193-7

In search of moderators and mediators of hyperglycemia with atypical antipsychotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3193-7

Metformin for weight control in pediatric patients on atypical antipsychotic medication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3193-7

Oiling the brain: a review of randomized controlled trials of omega-3 fatty acids in psychopathology across the lifespan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3193-7

Olanzapine, but not aripiprazole, weight-independently elevates serum triglycerides and activates lipogenic gene expression in female rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3193-7

Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3193-7

Selective hepatic insulin resistance, VLDL overproduction, and hypertriglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3193-7

Hypertriglyceridemia secondary to obesity and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3193-7

Adipose tissue dysfunction and hypertriglyceridemia: mechanisms and management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3193-7

Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3193-7

Olanzapine-induced accumulation of adipose tissue is associated with an inflammatory state

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3193-7

Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3193-7

Improvement In Indices Of Health Status In Outpatients With Schizophrenia Switched To Ziprasidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3193-7

Olanzapine induces SREBP-1-related adipogenesis in 3T3-L1 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3193-7

Evidence for an effect of clozapine on the regulation of fat-cell derived factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3193-7

Sterol Regulatory Element–Binding Protein-1 Determines Plasma Remnant Lipoproteins and Accelerates Atherosclerosis in Low-Density Lipoprotein Receptor–Deficient Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3193-7

An exploratory study examining lipid-lowering medications in reducing fasting serum lipids in schizophrenia patients treated with atypical antipsychotics

21 January 2018

1 reference

12 December 2020

Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.

1 reference

12 December 2020

The effects of novel antipsychotics on glucose and lipid levels.

1 reference

12 December 2020

Alterations of lipid metabolism and gene expression in rat adipocytes during chronic olanzapine treatment

1 reference

12 December 2020

Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorder

1 reference

12 December 2020

[Dyslipidemia and schizophrenia]

1 reference

12 December 2020

Regional variation in adipose tissue metabolism of severely obese premenopausal women.

1 reference

12 December 2020

Hypertriglyceridemia associated with direct effects of olanzapine rather than with weight gain: a case report

1 reference

12 December 2020

The Underlying Mechanisms for Olanzapine-induced Hypertriglyceridemia

1 reference

12 December 2020

Clozapine enhances differentiation of adipocyte progenitor cells

1 reference

12 December 2020

Increased expression of lipid biosynthesis genes in peripheral blood cells of olanzapine-treated patients

1 reference

12 December 2020

Impaired postprandial clearance of triacylglycerol-rich lipoproteins in adipose tissue in obese subjects

1 reference

12 December 2020

Effects of atypical antipsychotics on weight and serum lipid levels

1 reference

12 December 2020

Planning for the optimal design of studies to personalize antipsychotic prescriptions in the post-CATIE era: the clinical and pharmacoepidemiological data suggest that pursuing the pharmacogenetics of metabolic syndrome complications (hypertension,

1 reference

12 December 2020

Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice

1 reference

12 December 2020

Transcriptional activities of nuclear SREBP-1a, -1c, and -2 to different target promoters of lipogenic and cholesterogenic genes

1 reference

12 December 2020

SREBP activation by antipsychotic- and antidepressant-drugs in cultured human liver cells: relevance for metabolic side-effects?

1 reference

12 December 2020

Hyperlipidemia following treatment with antipsychotic medications.

1 reference

12 December 2020

Polyunsaturated fatty acid supplementation for schizophrenia

1 reference

12 December 2020

A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year

1 reference

12 December 2020

10.1007/S00213-013-3193-7

Identifiers

DOI

1 reference

Dimensions Publication ID

29 August 2017

1015907906

0 references

1 reference